SCHEMBL20911902

SCHEMBL20911902

Cc1cccc(-n2cc(-c3ccc(F)cc3)c3c(=O)[nH]cnc32)c1

nearest known ligand 0.83

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.83
LMNA P02545 7/20 0.83
KMT2A Q03164 4/20 0.83
HTT P42858 2/20 0.64
SRC P12931 1/20 0.63
GAA P10253 2/20 0.55
PKM P14618 1/20 0.54
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48
MEN1 O00255 3/20 0.47
KDM4E B2RXH2 1/20 0.47
ALDH1A1 P00352 1/20 0.47
UBE2N P61088 1/20 0.46
TP53 P04637 2/20 0.44
BRD4 O60885 1/20 0.44
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20911957 0.91 MAPT (1.00) MAPTLMNAKMT2AHTTSRC
SCHEMBL20912174 0.87 MAPT (0.90) MAPTLMNAKMT2AHTTSRC
SCHEMBL20911883 0.86 MAPT (0.80) MAPTLMNAKMT2AHTTSRC
SCHEMBL20911886 0.86 MAPT (0.80) MAPTLMNAKMT2AHTTSRC
SCHEMBL20911911 0.85 MAPT (0.71) MAPTLMNAKMT2AHTTSRC
SCHEMBL20911910 0.85 MAPT (0.90) MAPTLMNAKMT2AHTTSRC
SCHEMBL26661777 0.84 MAPT (0.87) MAPTLMNAKMT2AHTTSRC
SCHEMBL20911898 0.83 MAPT (1.00) MAPTLMNAKMT2AHTTSRC
SCHEMBL20912107 0.80 MAPT (0.70) MAPTLMNAKMT2AHTTSRC
SCHEMBL2800044 0.80 SRC (0.60) MAPTLMNAKMT2AHTTSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 US disclosed
US-11795169-B2 MAP4K4 inhibitors IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-10-24 US disclosed
US-20200339583-A1 MAP4K4 INHIBITORS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2020-10-29 US disclosed
WO-2019073253-A1 MAP4K4 INHIBITORS IMPERIAL INNOVATIONS LIMITED (GB) 2019-04-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200339583-A1 MAP4K4 INHIBITORS MAP4K4, MAP4K2, MAP4K5 MAPT 315/4885LMNA 4334/4885KMT2A 1775/4885
US-11795169-B2 MAP4K4 inhibitors MAP4K4, MAP4K2, MAP4K5 MAPT 315/4885LMNA 4334/4885KMT2A 1775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.